Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

CORFEDITING

Financiado

Gene Editing as Therapeutic Strategy for C9ORF72 Linked ALS FTD

Expansion of a hexanucleotide repeat G4C2 in the non-coding region of chromosome 9 open reading frame 72 (C9orf72) is the most common genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is... ver más

30/11/2018

USFD

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE UNIVERSITY OF SHEFFIELD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

2 Participantes

USFD

150.00K€ | Lider

THROMBOTARGETS EUROPE

400.00K€ | Participante

Proyectos interesantes

RTC-2015-3750-1 DESARROLLO DE AGENTES TERAPÉUTICOS BASADOS EN ÁCIDOS NUCLEIC... 392K€ Cerrado

HOMEOBRAIN Homeoproteins as novel therapies for neurodegenerative disea... 6M€ Cerrado

FRATAXAV Pre-clinical validation of a novel gene therapy for a rare d... 75K€ Cerrado

ADRIAN Multimodal Brain Imaging – Gene Relationships in Alzheimer D... 181K€ Cerrado

PID2019-104700GA-I00 TAXONOMIA DE LA UNION DE FACTORES DE TRANSCRIPCION EN EL GEN... 155K€ Cerrado

EpiAAVTherapy Characterizing the chromatin landscape of Spinal Muscular At... 196K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 19 meses Fecha Inicio: 2017-04-28
Fecha Fin: 2018-11-30

Líder del proyecto

THE UNIVERSITY OF SHEFFIELD

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Expansion of a hexanucleotide repeat G4C2 in the non-coding region of chromosome 9 open reading frame 72 (C9orf72) is the most common genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is a fatal condition characterized by progressive motor deficits, degeneration of upper and lower motor neurons (MNs) and death from neuromuscular respiratory failure in the majority of afflicted individuals within 3-5 years. Currently, the economic burden of care and treatment for patients with ALS/FTD is expensive and continues to significantly rise in Europe and worldwide. While significant genetic discoveries have been made in the field, they have not yet translated to treatment options for patients with ALS and FTD. Thus, research efforts aimed at identifying therapeutic targets are of the utmost importance to enable therapeutic development for these devastating disorders. In this ERC Proof of Concept project, we will design, optimise and test gene therapy vectors containing CRISPR/Cas9 system to selectively remove the pathogenic ALS/FTD-related C9orf72 hexanucleotide repeat expansion in mouse models of C9orf72-related ALS, with the ultimate aim of designing a therapy for patients with C9orf72-related ALS/FTD. The ultimate benefit of this approach goes far beyond just ALS/FTD however. A successful CNS gene therapy for C9orf72 related disease potentiates the prospect of developing similar approaches to treat multiple disease scenarios amenable to gene modification. Indeed, growing evidence suggests that C9orf72 repeat expansions also contribute to a wide spectrum of neurodegenerative diseases such as Alzheimer’s, Huntington’s, multiple sclerosis, Parkinson’s disease and cerebellar ataxias. We therefore anticipate that our strategy could be beneficial for other neurological conditions.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores